Elevated Endothelial MicroParticle-Monocyte Complexes Induced By Multiple Sclerosis Plasma And The Inhibitory Effects Of Interferon-ß-1b On Release Of Endothelial MicroParticles, Formation And TransEndothelial Migration Of Monocyte-Endothelial MicroParticle Complexes
Jimenez J, Jy W, Mauro LM, Horstman LL, Ahn ER, Ahn YS, Minagar A
Mult Scler 2005 Jun;11(3):310-5
University of Miami School of Medicine, Division of Hematology/Oncology, Wallace H Coulter Platelet Laboratory, Miami, FL 33136, USA
Monocyte migration through the disrupted Cerebral Endothelial Cell (EC) junctions plays an essential role in formation of Multiple Sclerosis (MS) DeMyelinating lesions.
During pathogenesis of MS, activated ECs release Endothelial MicroParticles (EMP), which possibly facilitate TransEndothelial migration (TEMIG) of Monocytes.
To assess functional roles of EMP in MS, specifically, their:
- Interaction with Monocytes
- Effect on Monocyte TEMIG in an in vitro model of
- Brain MicroVascular Endothelial Cells (BMVEC)
- Phenotypic profiles of EMP elicited by MS Plasma
- The effects of IFN-ß-1b on release of EMP and on
- TEMIG of Monocytes (Mono) and Monocytes:EMP complexes (Mono:EMP) through the BMVEC
The effect of IFN-ß-1b on the release of EMP and the TEMIG of Mono and Mono:EMP was assessed by preincubating BMVEC cultures of IFN-ß 1b prior to addition of plasma.
Three EMP phenotypes, CD54, CD62E and CD31 were assayed. Plasma specimens from 20 patients with Relapsing/Remitting MS (11 in exacerbation, MS-E, and 9 in remission, ME-R) and 10 healthy controls were studied.
Incubation of BMVEC with MS-E plasma yielded elevated levels of EMPCD54, EMP62E and EMPCD31 relative to MS-R and control Plasmas.
MS-E but not MS-R or control Plasma also augmented TEMIG of Monocytes, respectively.
Mono:EMP complexes further augmented TEMIG relative to Mono alone, but only in the presence of MS-E Plasma; there was no significant effect with MS-R or control Plasmas.
The presence of IFN-ß-1b inhibited TEMIG of Mono and Mono:EMP by 20% and 30%, respectively.
MS-E but not MS-R plasma elicited release of activation-derived EMP and enhanced TEMIG of Mono and Mono:EMP.
IFN-ß-1b inhibited TEMIG and release of EMP, suggesting a role of EMP and a novel therapeutic mechanism for IFN-ß-1b in MS.
Motor Cortex Excitability And Fatigue In Multiple Sclerosis: A TransCranial Magnetic Stimulation Study
Liepert J, Mingers D, Heesen C, Baumer T, Weiller C
Mult Scler 2005 Jun;11(3):316-21
University Hospital Eppendorf, Department of Neurology, Hamburg, Germany
We investigated ElectroPhysiological correlates of Fatigue in patients with Multiple Sclerosis (MS).
TransCranial Magnetic Stimulation (TMS) was used to explore motor excitability in three groups of subjects: MS patients with Fatigue (MS-F), MS patients without Fatigue (MS-NF) and healthy control subjects.
All participants had to perform a fatiguing hand-grip exercise. TMS was performed prior to and after the exercise. Prior to the Motor Task, MS-F patients had less inhibition in the Primary Motor Cortex compared to both other groups.
Postexercise, IntraCortical Inhibition was still reduced in the MS-F patients compared to the MS-NF patients. In MS-F patients the postexercise time interval for normalization of the Motor Threshold was correlated with the Fatigue severity.
We conclude that MS patients with Fatigue have an impairment of Inhibitory Circuits in their Primary Motor Cortex. The results also indicate that Fatigue severity is associated with an exercise-induced reduction of membrane excitability.
Severity Of Chronic Pain And Its Relationship To Quality Of Life In Multiple Sclerosis
Kalia LV, O'Connor PW
Mult Scler 2005 Jun;11(3):322-7
University of Toronto, Department of Neurology, Ontario M5B 1W8, Canada
This study used reliable and validated instruments to compare Pain severity in Multiple Sclerosis (MS) to that in other chronic painful conditions, and to examine relationships between chronic Pain in MS and health-related quality of life (HRQOL).
Ninety-nine MS patients completed a self-administered survey comprised of the Medical Outcomes 36-Item Short-Form Health Survey, the Short-Form McGill Pain Questionnaire, and the Hospital Anxiety and Depression Scale.
Pain severity was not different between MS patients with pain and Rheumatoid Arthritis (P = 0.77) or OsteoArthritis (P = 0.98) patients.
Chronic Pain in MS was less often Neurogenic than Non-Neurogenic, although severity of Neurogenic Pain was greater than that of Non-Neurogenic Pain (P = 0.048).
Chronic pain in MS was found to have no significant relationship to age, disease duration or disease course.
Instead, we found that pain was correlated with aspects of HRQOL, particularly mental health (r = 0.44, P < 0.0001) versus physical functioning (r = 0.19, P > 0.05).
Chronic pain was significantly related to Anxiety and Depression for females but not for males with MS.
Chronic pain in MS is as severe as pain in Arthritic conditions and is associated with reduced HRQOL. Thus, pain can be a significant symptom for MS patients and the need for treatment may be underestimated.
Accuracy Of Two Electronic Pedometers For Measuring Steps Taken Under Controlled Conditions Among Ambulatory Individuals With Multiple Sclerosis
Motl RW, McAuley E, Snook EM, Scott JA
Mult Scler 2005 Jun;11(3):343-5
University of Illinois at Urbana-Champaign, Department of Kinesiology, 332 Freer Hall, Urbana, IL 61801, USA
Pedometers are inexpensive and user-friendly devices that might be practical for measuring physical activity among individuals with Multiple Sclerosis (MS).
This study involved an evaluation of the accuracy of two pedometers against actual steps taken under controlled laboratory conditions (five minute bouts of walking at five different treadmill speeds [41, 54, 67, 80, and 94 m x min(-1)]) among 23 individuals with MS who were ambulatory without an aide.
Both pedometers exhibited good accuracy with the 67, 80, and 94 m x min(-1) speeds, but poor accuracy with the 41 and 54 m x min(-1) speeds.
Those results support the quantification of physical activity using pedometers among those with MS who are ambulatory without an aide.
Autologous Stem Cell Transplantation As Rescue Therapy In Malignant Forms Of Multiple Sclerosis
Mancardi GL, Murialdo A, Rossi P, Gualandi F, Martino G, Marmont A, Ciceri F, Schenone A, Parodi RC, Capello E, Comi G, Uccelli A
Mult Scler 2005 Jun;11(3):367-71
University of Genoa, Ophthalmology and Genetics, Department of NeuroSciences, Genoa, Italy
Malignant forms of Multiple Sclerosis (MS) represent a limited group of very aggressive DeMyelinating Diseases, which rapidly progress to severe disability leading often to life-threatening conditions.
On these clinical entities, currently available therapies for MS are not very effective.
Recently, it has been demonstrated that intense ImmunoSuppression followed by Autologous Stem Cell Transplantation (ASCT) can affect the clinical course of individuals with severe MS.
And completely abrogate the inflammatory activity detected by Magnetic Resonance Imaging (MRI).
We report on the treatment with intense Immune ablation followed by ASCT of three patients with malignant MS whose clinical course indicated a dramatically poor prognosis.
This procedure succeeded in halting the rapidly worsening course of disease.
The effect was long lasting, as demonstrated by a sustained efficacy over a two-year period in two subjects and 12 months in the third case.
In addition, a striking effect on inflammation-related MRI findings was obtained.
These results support a role for intense ImmunoSuppression followed by ASCT as treatment in rapidly evolving malignant MS cases unresponsive to conventional therapies.
One-Year Cyclophosphamide Treatment Combined With MethylPrednisolone Improves Cognitive Dysfunction In Progressive Forms Of Multiple Sclerosis
Zephir H, de Seze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, Ferriby D, Stojkovic T, Vermersch P
Mult Scler 2005 Jun;11(3):360-3
University of Lille II and CHR, Hopital Roger Salengro, Department of Neurology, 59047 Lille, France
We conducted an evaluation of changes in Cognition in Progressive Multiple Sclerosis (MS) patients receiving monthly intravenously pulse of Cyclophosphamide (700 mg/m2) with MethylPrednisolone (1g).
Twenty-eight consecutive Progressive MS patients (10 Primary/Progressive, 18 Secondary/Progressive MS) were evaluated before and after six and 12 months of treatment.
The WAIS-R score, Memory and Executive Functions were evaluated.
Under treatment we found a significant improvement in global Cognitive efficiency, encoding abilities, planning abilities and inhibition after six and 12 months.
However, mechanisms of action of the positive effect of these Anti-Inflammatory and ImmunoSuppressive treatments on Cognition remain unclear.
Hereditary Melkersson-Rosenthal Syndrome And Multiple Sclerosis
Cabrera-Gomez JA, Echazabal-Santana N, Real-Gonzalez Y, Romero Garcia K, Junior Sobrinho M, Gil Ocana MA, Gonzalez-Valdes N, Valdes-Montesde Oca ML, Cristofo-Corominas M, Gonzalez de la Nuez J, Garcia Lahera J, Ugarte Suarez C
Mult Scler 2005 Jun;11(3):364-6
International Center of Neurologic Restoration (CIREN), Avenida 25 #15805 entre 158 y 160, Reparto Cubanacan, Playa, Ciudad de La Habana, Cuba
The revision of MEDLINE from 1966 to 2003 did not report any association between Multiple Sclerosis (MS) and Melkersson-Rosenthal Syndrome (MRS).
This is a case report of a 51-year-old woman, with history of four recurrent Bell's Palsies.
In 1999 she developed a right facial paralysis due to a SupraNuclear Pyramidal lesion with Right MonoParesis.
The family history showed five relatives with recurrent Bell's Paralysis and plicata tongue.
Physical examination: Right Bell's paralysis, Left Supranuclear facial paralysis, furrowed tongue, Right HemiParesis with pallor of the Optic Disks.
Brain Magnetic Resonance Imaging (MRI) demonstrated the typical lesions of MS and CSF OligoClonal Bands. This is the first observation of a patient with hereditary MRS and MS.
The link between both diseases is discussed.